Trial Search Results

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer

Primary objective was to demonstrate overall survival improvement with aflibercept compared to placebo in patients receiving docetaxel / prednisone for metastatic androgen-independent prostate cancer (MAIPC).

The secondary objectives were:

- To assess the efficacy of aflibercept compared to placebo on other parameters such prostate-specific antigen (PSA) level, cancer related pain, progression free survival (PFS), tumor-based and skeletal events and health-related quality of life (HRQL);

- To assess the overall safety in both treatment arms;

- To determine the pharmacokinetics of intravenous (IV) aflibercept in this population;

- to determine immunogenicity of IV aflibercept.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:


Collaborator: Regeneron Pharmaceuticals

Stanford Investigator(s):


  • Drug: Aflibercept
  • Drug: Placebo (for aflibercept)
  • Drug: Docetaxel
  • Drug: Prednisone or Prednisolone


Phase 3


Inclusion Criteria:

   - Histologically- or cytologically-confirmed prostate adenocarcinoma;

   - Metastatic disease;

   - Progressive disease while receiving hormonal therapy or after surgical castration;

   - Effective castration.

Exclusion Criteria:

   - Prior cytotoxic chemotherapy for prostate cancer, except estramustine and except
   adjuvant/neoadjuvant treatment completed >3 years ago;

   - Prior treatment with Vascular Endothelial Growth Factor (VEGF) inhibitors or VEGF
   receptor inhibitors;

   - Eastern Cooperative Oncology Group (ECOG) performance status >2.

The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting